The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 16 of the 37 sources its claims cite were checked for support.
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
Open accessAbstract
A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4─139] weeks. The median AEC was 2.7 [0.8─90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.
Overview
CoChat Summary
TL;DR
In 37 cases of moderate-to-severe eosinophilia after immune checkpoint inhibitor (ICI) therapy, eosinophil-related manifestations occurred in 21/37 (57%), with median time to absolute eosinophil count (AEC) peak of 15 weeks and median AEC of 2.7 G/L. Corticosteroids were effective in all 10 treated patients, and some patients had remission without corticosteroids after ICI discontinuation or continuation.
Key findings
- Among 37 included reports, 25 patients received nivolumab, 6 pembrolizumab, 4 ipilimumab, and 2 nivolumab plus ipilimumab; indications were non-small-cell lung cancer (n = 18), melanoma (n = 18), and Hodgkin’s lymphoma (n = 1).
- Median [range] time to new-onset eosinophilia was 6 [1─52] weeks and to AEC peak was 15 [4─139] weeks; median AEC was 2.7 [0.8─90.9] G/L.
- Eosinophil-related manifestations were reported in 21/37 cases (57%), affecting skin (n = 10), lung (2 eosinophilic pneumonia, 2 eosinophilic bronchiolitis), kidneys (4 nephritis), liver (2 cholangitis), and heart (1 myocarditis); severity included 1 grade IV, 6 grade III, 8 grade II, and 7 grade I cases, with no deaths attributable to Eo-irAEs.
- Corticosteroids were always effective when administered (n = 10/10); partial or complete remission also occurred in some patients not treated with corticosteroids after ICI discontinuation (n = 12) or continuation (n = 4).
Methods
- Observational study of cases recorded at the French national reference center for hypereosinophilic syndromes (CEREO) and the French national pharmacovigilance database (FPVD), searched up to January 15, 2019 and November 1, 2017, respectively.
- Inclusion required at least one AEC >1 G/L after ICI initiation and/or biopsy-confirmed eosinophil-induced organ damage; patients with other likely eosinophilia etiologies or missing data were excluded.
- Cases were classified as Eo-ir (no organ dysfunction attributed to eosinophilia) or Eo-irAEs (organ dysfunction considered induced by proven tissue eosinophilia and/or potentially induced by eosinophils); quantitative variables were reported as median [range], and medians compared using Wilcoxon rank sum test.
Limitations
- The authors state that the retrospective design had inherent limitations: misclassification, missing data, and risk of selection bias due to the FPVD’s self-reporting procedure, which emphasizes the most symptomatic cases.
- The authors note that data on time from corticosteroid onset to remission were not available for the great majority of cases, and corticosteroid dosage was not specified in the pharmacovigilance reports.
- The text makes evident that this is a descriptive case series without a control group, so comparative effectiveness or causality cannot be established from these data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
9 Valid · 0 Not valid · 10 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“multiple recent reports of Eo-irAEs like eosinophilic fasciitis27-30 or eosinophilic granulomatosis with polyangiitis31 suggest that topical or low-dose oral corticosteroids, with or without CS-sparing treatments, can give excellent results.”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Discussion
What the sources say
- Not checked — no full text of the sourcecites [27] Toussaint F, Hammon M, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Schett G, Heinzerling L. Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. Rheumatology. 2019;58(10):1875–1877. doi: 10.1093/rheumatology/kez164. 31056673 source
- Not checked — no full text of the sourcecites [28] Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, Butler MO, Rogalla P, Mason W, Joshua AM, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016; 4(3): 175– 178. doi: 10.1158/2326-6066.CIR-15-0186. 26822024 source
- Not checked — no full text of the sourcecites [29] Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018; 17(3): 284– 289. doi: 10.1016/j.autrev.2018.01.003. 29341936 source
- Not checked — no full text of the sourcecites [30] Andrés‐Lencina -J-J, Burillo‐Martínez S, Aragón‐Miguel R, Calleja‐Algarra A, Rodríguez‐Peralto J-L, Ortiz‐Romero P-L, Gargallo‐Moneva V. Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab. Australas J Dermatol. 2018; 59(4): e302– e304. doi: 10.1111/ajd.12836. 29797309 source
- Partly supportedcites [31] Roger A, Groh M, Lorillon G, Pendu CL, Maillet J, Arangalage D, Tazi A, Lebbe C, Baroudjian B, Delyon J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. Ann Rheum Dis. 2019; 78(8): e82– e82. doi: 10.1136/annrheumdis-2018-213857. 29936437 sourceExperimental — accuracy not yet measured
The EGPA case report describes rapid improvement after inhaled corticosteroids and a long-acting beta-agonist, and later treatment with inhaled therapy and an intra-articular corticosteroid injection (case description; page unavailable). It does not report treatment with topical or low-dose oral corticosteroids or a corticosteroid-sparing drug. Symptoms also worsened despite continued inhaled therapy when nivolumab was reintroduced, so the claimed excellent results from the stated regimens are not established by this case. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included.”
- Also stated in: § Results · plain
“Thirty-seven patients were included in the study (Figure 1): 25 were treated with nivolumab, 6 with pembrolizumab, 4 with ipilimumab, and 2 with a combination of nivolumab and ipilimumab (1 case with the two drugs concomitantly, and 1 case with a switch from ipilimumab to nivolumab).”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Abstract
plainstates a causen = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
In the paper
“Similarly, the median time to the AEC peak observed in our study (3.4 months [1─32.4]), was shorter than that observed by Berrnard-Teissier et al. (6.4 months [1.4─32]).”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Discussion
What the sources say
- Not checked — no full text of the sourcecites [6] Bernard-Tessier A, Jeanville P, Champiat S, Lazarovici J, Voisin A-L, Mateus C, Lambotte O, Annereau M, Michot J-M. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer. 2017; 81: 135– 137. doi: 10.1016/j.ejca.2017.05.017. 28624693 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the cohort as a whole, the median times to new-onset eosinophilia and to the AEC peak were respectively 6 [1─52] and 15 [4─139] weeks after ICI initiation.”
- Also stated in: § Discussion · plain
“Considering the time to new-onset eosinophilia (median [range]: 6 weeks [1─52] or 1.4 months [0.2─12])”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4─139] weeks.”
- Also stated in: § Results · plain
“In the cohort as a whole, the median times to new-onset eosinophilia and to the AEC peak were respectively 6 [1─52] and 15 [4─139] weeks after ICI initiation.”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
19 more claims
Create a free account to see all 56 claims and every source verdict.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 20
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“With regard to the severity of the Eo-irAEs, there were 1 grade IV case, 6 grade III cases, 8 grade II cases and 7 grade I cases.”
§ Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database > Results
Reported 21 · recomputed 22
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions; indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at le…”
BackgroundImmune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · cited 3×
“The time to onset of moderate-to-severe eosinophilia reported in our study is in line with that described for other irAEs that typically arise within a few weeks or months of ICIinitiation.7 Given our stringent inclusion criteria, our objective here was to describe the patients with the most severe ICI-induced AEs; ac…”
ResultCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“However, these molecules can be specifically targeted by immune checkpoint inhibitors (ICIs), such as ipilimumab (a monoclonal antibody against the cytotoxic T-lymphocyte antigen 4 (CTLA4)), nivolumab, and pembrolizumab (both of which target programmed cell death protein 1 (PD1) or its ligand (PD-L1)).(1) These drugs…”
BackgroundBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · cited 1×
“Although an effective ICI may not have to be discontinued after a mild irAE, specific treatments and/or discontinuation of the ICI must be considered in the most severe cases.(5) In a recent retrospective single-center study, the prevalence of immune-related blood eosinophilia (an absolute eosinophil count (AEC) great…”
BackgroundHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 1×
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions; indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at le…”
Backgroundon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,390 · cited 1×
“In the FPVD, cases were selected using logical combinations of the MedDRA preferred terms “eosinophilia”, “eosinophil count abnormal”, “eosinophil count increased”, “eosinophil percentage abnormal”, “eosinophil percentage increased”, “eosinophilic cellulitis”, “eosinophilic fasciitis”, “eosinophilic pustular folliculi…”
MethodManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903 · cited 2×
“These drugs have been approved for the treatment of several cancers, including melanoma, non-small-cell lung cancer, urothelial carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and the neck, and/or Hodgkin’s lymphoma.(2) However, ICIs are also associated with frequent and potentially organ- or life…”
BackgroundBaseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Cited by
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241
Opposing roles of eosinophils in cancer
Simon, S. C. S., Utikal, J., & Umansky, V. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2255-4 · Cited by 128
Clinical and translational attributes of immune-related adverse events
Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 146
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Melero, I., Tanos, T., Bustamante, M., Sanmamed, M. F., Calvo, E., Moreno, I., Moreno, V., Hernández‐Guerrero, T., Martinez‐García, M., Rodríguez‐Vida, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abp9229 · Cited by 91
Metadata
- Authors
- Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., Staumont-Sallé, D., Morschhauser, F., Forestier, A., Groh, M., Launay, D., Hachulla, E., Labalette, M., Kahn, J.-E., & Lefèvre, G.
- Affiliations
- Université de Lille (FR)
- CHU Dijon Bourgogne (FR)
- Hôpital Européen Georges Pompidou, Centre Régional de PharmacoVigilance, Assistance Publique-Hôpitaux de Paris
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Oscar Lambret (FR)
- Corresponding author
- Lefèvre, Guillaume
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- 9
- Issue
- 1
- Pages
- 1722022-1722022
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC7153834
- OpenAlex
- W3016188779
- Cited by
- 59
- References
- 38
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 13 · 2023: 7 · 2022: 8 · 2021: 13 · 2020: 2
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, drug-induced eosinophilia, immune-related adverse events, hypereosinophilic syndrome, absolute eosinophil count, corticosteroid therapy, treatment discontinuation, immune-related pneumonitis, pharmacovigilance
- MeSH terms
- Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Humans, Databases, Factual, Hypereosinophilic Syndrome, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. https://app.cochat.ai/papers/10.1080/2162402x.2020.1722022
- The paper
- Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., Staumont-Sallé, D., Morschhauser, F., Forestier, A., Groh, M., Launay, D., Hachulla, E., Labalette, M., Kahn, J.-E., & Lefèvre, G. (2020). Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1722022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
